EXACT Sciences Stock Price, News & Analysis (NASDAQ:EXAS)

$50.22 -1.74 (-3.35 %)
(As of 12/13/2017 01:57 AM ET)
Previous Close$51.96
Today's Range$48.35 - $51.77
52-Week Range$13.05 - $63.60
Volume4.43 million shs
Average Volume2.47 million shs
Market Capitalization$6.45 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.67

About EXACT Sciences (NASDAQ:EXAS)

EXACT Sciences logoExact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:EXAS
CUSIP30063P10
Phone608-284-5700

Debt

Debt-to-Equity Ratio0.01%
Current Ratio10.34%
Quick Ratio9.98%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$99.38 million
Price / Sales60.50
Cash FlowN/A
Price / CashN/A
Book Value$3.09 per share
Price / Book16.25

Profitability

Trailing EPS($1.16)
Net Income$-167,210,000.00
Net Margins-60.71%
Return on Equity-30.32%
Return on Assets-27.37%

Miscellaneous

Employees736
Outstanding Shares119,730,000

EXACT Sciences (NASDAQ:EXAS) Frequently Asked Questions

What is EXACT Sciences' stock symbol?

EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."

How were EXACT Sciences' earnings last quarter?

EXACT Sciences Co. (NASDAQ:EXAS) posted its quarterly earnings results on Monday, October, 30th. The medical research company reported ($0.23) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.30) by $0.07. The medical research company earned $72.60 million during the quarter, compared to the consensus estimate of $65.03 million. EXACT Sciences had a negative return on equity of 30.32% and a negative net margin of 60.71%. The business's revenue was up 158.4% compared to the same quarter last year. During the same period last year, the company earned ($0.36) earnings per share. View EXACT Sciences' Earnings History.

When will EXACT Sciences make its next earnings announcement?

EXACT Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, February, 20th 2018. View Earnings Estimates for EXACT Sciences.

Where is EXACT Sciences' stock going? Where will EXACT Sciences' stock price be in 2017?

13 brokerages have issued 12-month target prices for EXACT Sciences' shares. Their forecasts range from $28.00 to $67.00. On average, they anticipate EXACT Sciences' stock price to reach $51.46 in the next year. View Analyst Ratings for EXACT Sciences.

What are Wall Street analysts saying about EXACT Sciences stock?

Here are some recent quotes from research analysts about EXACT Sciences stock:

  • 1. According to Zacks Investment Research, "EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. " (11/2/2017)
  • 2. Cowen Inc analysts commented, "Colon cancer is the #2 cause of cancer death in the US, yet compliance with screening guidelines is low. Exact Sciences' Cologuard is less invasive than colonoscopy, more accurate than alternatives, FDA approved, in guidelines, and increasingly reimbursed. EXAS is targeting $4B of a ~$15B annual market opportunity. The 5-year revenue CAGR is forecast at ~50%. Initiate at Outperform with a $30 PT." (3/27/2017)

Who are some of EXACT Sciences' key competitors?

Who are EXACT Sciences' key executives?

EXACT Sciences' management team includes the folowing people:

  • Kevin T. Conroy, Chairman of the Board, President, Chief Executive Officer (Age 51)
  • Jeffrey Thomas Elliott, Chief Financial Officer (Age 39)
  • Maneesh K. Arora, Chief Operating Officer, Senior Vice President, Director (Age 48)
  • Graham Peter Lidgard Ph.D., Senior Vice President, Chief Scientific Officer (Age 68)
  • D. Scott Coward, Senior Vice President, General Counsel, Secretary (Age 52)
  • David A. Thompson, Lead Independent Director (Age 75)
  • Thomas D. Carey, Independent Director (Age 55)
  • James E. Doyle, Independent Director (Age 71)
  • John A. Fallon M.D., Independent Director (Age 69)
  • Daniel J. Levangie, Independent Director (Age 66)

Who owns EXACT Sciences stock?

EXACT Sciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (2.40%), Gilder Gagnon Howe & Co. LLC (2.12%), Zevenbergen Capital Investments LLC (1.77%), Eagle Asset Management Inc. (1.53%), Wasatch Advisors Inc. (1.30%) and Canada Pension Plan Investment Board (0.78%). Company insiders that own EXACT Sciences stock include D Scott Coward, David Thompson, Graham Peter Lidgard, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Napier, Katherine S Zanotti, Kevin T Conroy, Lionel Sterling, Maneesh Arora and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences.

Who sold EXACT Sciences stock? Who is selling EXACT Sciences stock?

EXACT Sciences' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Gilder Gagnon Howe & Co. LLC, Elk Creek Partners LLC, Wasatch Advisors Inc., Neuberger Berman Group LLC, Victory Capital Management Inc., Zevenbergen Capital Investments LLC and Skylands Capital LLC. Company insiders that have sold EXACT Sciences company stock in the last year include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Kevin T Conroy and Maneesh Arora. View Insider Buying and Selling for EXACT Sciences.

Who bought EXACT Sciences stock? Who is buying EXACT Sciences stock?

EXACT Sciences' stock was purchased by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Canada Pension Plan Investment Board, Hodges Capital Management Inc., Baillie Gifford & Co., Schwab Charles Investment Management Inc., Russell Investments Group Ltd., Sectoral Asset Management Inc and Axiom International Investors LLC DE. Company insiders that have bought EXACT Sciences stock in the last two years include David Thompson, James Edward Doyle, Katherine S Napier, Katherine S Zanotti, Kevin T Conroy, Lionel Sterling and Thomas D Carey. View Insider Buying and Selling for EXACT Sciences.

How do I buy EXACT Sciences stock?

Shares of EXACT Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is EXACT Sciences' stock price today?

One share of EXACT Sciences stock can currently be purchased for approximately $50.22.

How big of a company is EXACT Sciences?

EXACT Sciences has a market capitalization of $6.45 billion and generates $99.38 million in revenue each year. The medical research company earns $-167,210,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. EXACT Sciences employs 736 workers across the globe.

How can I contact EXACT Sciences?

EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-284-5700.


MarketBeat Community Rating for EXACT Sciences (EXAS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  534 (Vote Outperform)
Underperform Votes:  303 (Vote Underperform)
Total Votes:  837
MarketBeat's community ratings are surveys of what our community members think about EXACT Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

EXACT Sciences (NASDAQ:EXAS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.602.602.732.73
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $47.53$46.93$38.73$32.47
Price Target Upside: 19.15% downside22.26% downside8.54% downside0.36% upside

EXACT Sciences (NASDAQ:EXAS) Consensus Price Target History

Price Target History for EXACT Sciences (NASDAQ:EXAS)

EXACT Sciences (NASDAQ:EXAS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/29/2017Bank of AmericaBoost Price TargetBuy$58.00 -> $67.00LowView Rating Details
11/13/2017Leerink SwannReiterated RatingOutperform$63.00 -> $67.00N/AView Rating Details
11/13/2017Robert W. BairdDowngradeOutperform -> Neutral$56.00N/AView Rating Details
11/1/2017BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
10/31/2017Canaccord GenuityUpgradeBuy$60.00N/AView Rating Details
10/31/2017Craig HallumBoost Price TargetBuy$46.00 -> $61.00N/AView Rating Details
10/31/2017BenchmarkReiterated RatingBuy -> Buy$50.00 -> $60.00N/AView Rating Details
10/31/2017Jefferies GroupBoost Price TargetBuy$60.00N/AView Rating Details
7/26/2017Roth CapitalBoost Price TargetBuy$40.00 -> $46.00HighView Rating Details
7/26/2017Lake Street CapitalBoost Price TargetHold -> Hold$30.00 -> $41.00MediumView Rating Details
6/7/2017StephensSet Price TargetHold$28.00MediumView Rating Details
5/31/2017CowenReiterated RatingOutperform$45.00HighView Rating Details
5/1/2017Goldman Sachs GroupSet Price TargetNeutral$21.00 -> $33.00MediumView Rating Details
7/27/2016MizuhoBoost Price TargetNeutral$10.00 -> $15.00N/AView Rating Details
7/15/2016William BlairReiterated RatingOutperform$29.00N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

EXACT Sciences (NASDAQ:EXAS) Earnings History and Estimates Chart

Earnings by Quarter for EXACT Sciences (NASDAQ:EXAS)

EXACT Sciences (NASDAQ EXAS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/19/2018($0.29)N/AView Earnings Details
10/30/2017Q3 2017($0.30)($0.23)$65.03 million$72.60 millionViewN/AView Earnings Details
7/25/2017Q2 2017($0.37)($0.27)$47.73 million$57.65 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.41)($0.32)$37.38 million$48.36 millionViewN/AView Earnings Details
2/21/2017Q416($0.39)($0.34)$32.53 million$35.24 millionViewListenView Earnings Details
10/26/2016Q316($0.43)($0.36)$25.24 million$28.10 millionViewListenView Earnings Details
7/26/2016Q216($0.55)($0.46)$18.54 million$21.20 millionViewListenView Earnings Details
5/3/2016Q116($0.52)($0.49)$15.17 million$14.80 millionViewN/AView Earnings Details
2/24/2016Q415($0.47)($0.41)$14.96 million$14.40 millionViewListenView Earnings Details
10/29/2015Q315($0.44)($0.45)$12.56 million$12.60 millionViewListenView Earnings Details
7/20/2015Q215($0.45)($0.44)$7.96 million$8.10 millionViewListenView Earnings Details
5/4/2015Q115($0.41)($0.40)$4.11 million$4.30 millionViewN/AView Earnings Details
2/24/2015Q414($0.39)($0.38)$19.90 million$1.15 millionViewN/AView Earnings Details
10/27/2014Q314($0.34)($0.39)$0.13 millionViewListenView Earnings Details
7/22/2014Q214($0.25)($0.24)$0.03 millionViewN/AView Earnings Details
5/1/2014Q114($0.19)($0.23)$0.40 million$0.30 millionViewN/AView Earnings Details
2/20/2014Q413($0.19)($0.17)$1.02 million$1.00 millionViewN/AView Earnings Details
10/29/2013Q313($0.18)($0.16)$1.02 million$1.00 millionViewN/AView Earnings Details
7/23/2013Q2 2013($0.18)($0.19)$1.02 million$1.00 millionViewN/AView Earnings Details
5/1/2013Q1 2013($0.20)($0.17)$1.02 million$1.00 millionViewN/AView Earnings Details
2/20/2013Q4 2012($0.18)($0.22)$1.04 million$1.00 millionViewN/AView Earnings Details
10/30/2012Q312($0.21)($0.21)$1.03 million$1.04 millionViewN/AView Earnings Details
7/25/2012($0.20)($0.26)ViewN/AView Earnings Details
5/1/2012($0.18)($0.19)ViewN/AView Earnings Details
2/23/2012($0.17)($0.18)ViewN/AView Earnings Details
11/3/2011($0.15)($0.15)ViewN/AView Earnings Details
8/2/2011($0.10)($0.13)ViewN/AView Earnings Details
5/3/2011($0.09)($0.08)ViewN/AView Earnings Details
2/15/2011($0.08)($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

EXACT Sciences (NASDAQ:EXAS) Earnings Estimates

2017 EPS Consensus Estimate: ($1.45)
2018 EPS Consensus Estimate: ($0.86)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.44)($0.40)($0.42)
Q2 20174($0.41)($0.33)($0.38)
Q3 20175($0.35)($0.28)($0.33)
Q4 20176($0.36)($0.29)($0.32)
Q1 20184($0.33)($0.24)($0.27)
Q2 20184($0.33)($0.18)($0.24)
Q3 20184($0.32)($0.10)($0.20)
Q4 20184($0.31)($0.03)($0.15)
Q1 20191($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for EXACT Sciences (NASDAQ:EXAS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

EXACT Sciences (NASDAQ EXAS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 82.39%
Insider Trades by Quarter for EXACT Sciences (NASDAQ:EXAS)
Institutional Ownership by Quarter for EXACT Sciences (NASDAQ:EXAS)

EXACT Sciences (NASDAQ EXAS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/6/2017Kevin T ConroyInsiderSell121,849$53.45$6,512,829.05View SEC Filing  
12/1/2017Graham Peter LidgardInsiderSell45,770$58.27$2,667,017.90View SEC Filing  
11/21/2017Kevin T ConroyInsiderSell134,057$59.50$7,976,391.50View SEC Filing  
11/9/2017Kevin T ConroyCEOSell137,805$59.14$8,149,787.70View SEC Filing  
11/1/2017Graham Peter LidgardInsiderSell45,775$53.60$2,453,540.00View SEC Filing  
10/2/2017D Scott CowardSVPSell29,115$47.16$1,373,063.40View SEC Filing  
10/2/2017Graham Peter LidgardInsiderSell81,025$47.16$3,821,139.00View SEC Filing  
9/5/2017Graham Peter LidgardInsiderSell75,683$40.81$3,088,623.23View SEC Filing  
9/1/2017Graham Peter LidgardInsiderSell45,775$41.49$1,899,204.75View SEC Filing  
8/17/2017Thomas D CareyDirectorBuy2,500$37.71$94,275.00View SEC Filing  
7/31/2017Jeffrey Thomas ElliottCFOSell5,846$39.41$230,390.86View SEC Filing  
7/3/2017D Scott CowardSVPSell1,987$35.21$69,962.27View SEC Filing  
4/3/2017D Scott CowardSVPSell1,543$23.74$36,630.82View SEC Filing  
3/13/2017D Scott CowardSVPSell1,983$21.16$41,960.28View SEC Filing  
3/13/2017Kevin T ConroyInsiderSell12,059$21.16$255,168.44View SEC Filing  
3/13/2017Maneesh AroraCOOSell5,574$21.16$117,945.84View SEC Filing  
2/27/2017D Scott CowardSVPSell7,046$21.48$151,348.08View SEC Filing  
2/27/2017Graham Peter LidgardInsiderSell8,668$21.51$186,448.68View SEC Filing  
2/27/2017Maneesh AroraCOOSell11,114$21.50$238,951.00View SEC Filing  
1/3/2017D Scott CowardSVPSell1,535$13.61$20,891.35View SEC Filing  
12/14/2016David ThompsonDirectorBuy10,000$13.84$138,400.00View SEC Filing  
11/15/2016Kevin T ConroyInsiderSell600,000$17.46$10,476,000.00View SEC Filing  
11/15/2016Maneesh AroraCOOSell562,932$17.46$9,828,792.72View SEC Filing  
9/1/2016Lionel SterlingDirectorBuy5,000$18.10$90,500.00View SEC Filing  
8/3/2016Katherine S ZanottiDirectorBuy3,380$17.93$60,603.40View SEC Filing  
7/26/2016Graham Peter LidgardInsiderSell7,383$14.82$109,416.06View SEC Filing  
7/26/2016Maneesh AroraCOOSell7,359$14.82$109,060.38View SEC Filing  
4/1/2016D Scott CowardSVPSell1,685$6.62$11,154.70View SEC Filing  
3/10/2016D Scott CowardSVPSell2,175$6.05$13,158.75View SEC Filing  
3/10/2016Graham Peter LidgardInsiderSell3,041$6.05$18,398.05View SEC Filing  
3/10/2016Maneesh AroraCOOSell4,042$6.05$24,454.10View SEC Filing  
3/8/2016James Edward DoyleDirectorBuy5,000$6.43$32,150.00View SEC Filing  
3/3/2016Katherine S NapierDirectorBuy3,775$5.38$20,309.50View SEC Filing  
3/1/2016Kevin T ConroyCEOBuy50,000$5.00$250,000.00View SEC Filing  
2/26/2016Kevin T ConroyCEOSell6,895$5.81$40,059.95View SEC Filing  
2/25/2016Graham Peter LidgardInsiderSell2,997$5.52$16,543.44View SEC Filing  
2/25/2016Maneesh AroraCOOSell4,099$5.52$22,626.48View SEC Filing  
2/23/2016Graham Peter LidgardInsiderSell2,411$6.39$15,406.29View SEC Filing  
2/23/2016Kevin T ConroyCEOSell6,866$6.39$43,873.74View SEC Filing  
2/23/2016Maneesh AroraCOOSell2,556$6.39$16,332.84View SEC Filing  
1/11/2016David ThompsonDirectorBuy15,000$6.99$104,850.00View SEC Filing  
2/26/2015Graham Peter LidgardDirectorSell3,938$23.44$92,306.72View SEC Filing  
2/26/2015Kevin T ConroyCEOSell8,425$23.44$197,482.00View SEC Filing  
2/26/2015Maneesh AroraCOOSell3,895$23.44$91,298.80View SEC Filing  
2/24/2015Graham Peter LidgardDirectorSell4,037$22.90$92,447.30View SEC Filing  
2/24/2015Kevin T ConroyCEOSell9,798$22.90$224,374.20View SEC Filing  
2/24/2015Maneesh AroraCOOSell2,995$22.90$68,585.50View SEC Filing  
1/2/2015Graham Peter LidgardInsiderSell3,363$26.72$89,859.36View SEC Filing  
1/2/2015Kevin T ConroyCEOSell9,484$26.72$253,412.48View SEC Filing  
1/2/2015Maneesh AroraCOOSell2,495$26.72$66,666.40View SEC Filing  
10/29/2014Graham Peter LidgardInsiderSell8,015$24.68$197,810.20View SEC Filing  
7/25/2014Graham Peter LidgardVPSell11,081$15.99$177,185.19View SEC Filing  
7/25/2014Kevin T ConroyCEOSell11,336$15.99$181,262.64View SEC Filing  
7/25/2014Maneesh AroraCOOSell9,291$15.99$148,563.09View SEC Filing  
5/5/2014William MeganSVPBuy10,000$11.79$117,900.00View SEC Filing  
2/24/2014Graham Peter LidgardVPSell3,160$14.07$44,461.20View SEC Filing  
2/24/2014Kevin ConroyCEOSell8,708$14.07$122,521.56View SEC Filing  
2/24/2014Maneesh AroraCOOSell2,662$14.07$37,454.34View SEC Filing  
1/2/2014Graham Peter LidgardVPSell10,288$11.96$123,044.48View SEC Filing  
1/2/2014Kevin ConroyCEOSell26,379$11.96$315,492.84View SEC Filing  
1/2/2014Maneesh AroraCOOSell8,627$11.96$103,178.92View SEC Filing  
10/28/2013Graham Peter LidgardVPSell7,430$11.07$82,250.10View SEC Filing  
9/20/2013Sally CrawfordDirectorSell25,000$12.19$304,750.00View SEC Filing  
11/2/2012Kevin T ConroyCEOBuy2,000$9.13$18,260.00View SEC Filing  
11/2/2012Maneesh AroraCFOBuy1,000$9.04$9,040.00View SEC Filing  
11/1/2012Lionel SterlingDirectorBuy5,500$9.08$49,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

EXACT Sciences (NASDAQ EXAS) News Headlines

Source:
DateHeadline
EXACT Sciences Corp. breached its 50 day moving average in a Bearish Manner : EXAS-US : December 12, 2017EXACT Sciences Corp. breached its 50 day moving average in a Bearish Manner : EXAS-US : December 12, 2017
finance.yahoo.com - December 12 at 10:09 AM
2 Growth Stocks You Won't Want to Miss2 Growth Stocks You Won't Want to Miss
finance.yahoo.com - December 11 at 10:26 AM
EXACT Sciences (EXAS) Stock Rating Lowered by BidaskClubEXACT Sciences (EXAS) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - December 10 at 3:46 PM
Exact Sciences Corp (EXAS) President and CEO Kevin T Conroy Sold $6.5 million of SharesExact Sciences Corp (EXAS) President and CEO Kevin T Conroy Sold $6.5 million of Shares
finance.yahoo.com - December 9 at 9:44 AM
Kevin T. Conroy Sells 121,849 Shares of EXACT Sciences Co. (EXAS) StockKevin T. Conroy Sells 121,849 Shares of EXACT Sciences Co. (EXAS) Stock
www.americanbankingnews.com - December 8 at 5:30 PM
Is Exact Sciences Corporation (EXAS) a Buy? - Motley FoolIs Exact Sciences Corporation (EXAS) a Buy? - Motley Fool
www.fool.com - December 8 at 9:42 AM
ETFs with exposure to EXACT Sciences Corp. : December 7, 2017ETFs with exposure to EXACT Sciences Corp. : December 7, 2017
finance.yahoo.com - December 7 at 5:33 PM
Is Exact Sciences Corporation (EXAS) a Buy?Is Exact Sciences Corporation (EXAS) a Buy?
finance.yahoo.com - December 7 at 10:00 AM
EXACT Sciences Co. (EXAS) Insider Sells $2,667,017.90 in StockEXACT Sciences Co. (EXAS) Insider Sells $2,667,017.90 in Stock
www.americanbankingnews.com - December 4 at 5:46 PM
Where Will Exact Sciences Corporation Be in 5 Years? - Motley FoolWhere Will Exact Sciences Corporation Be in 5 Years? - Motley Fool
www.fool.com - December 4 at 5:08 PM
Where Will Exact Sciences Corporation Be in 5 Years?Where Will Exact Sciences Corporation Be in 5 Years?
finance.yahoo.com - December 4 at 9:42 AM
Zacks: Analysts Anticipate EXACT Sciences Co. (EXAS) Will Announce Quarterly Sales of $76.55 MillionZacks: Analysts Anticipate EXACT Sciences Co. (EXAS) Will Announce Quarterly Sales of $76.55 Million
www.americanbankingnews.com - December 4 at 4:40 AM
Zacks: Analysts Anticipate EXACT Sciences Co. (EXAS) Will Post Earnings of -$0.29 Per ShareZacks: Analysts Anticipate EXACT Sciences Co. (EXAS) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - December 2 at 9:34 PM
Why 2017 Was a Year to Remember for Exact Sciences CorporationWhy 2017 Was a Year to Remember for Exact Sciences Corporation
finance.yahoo.com - December 1 at 5:03 PM
EXACT Sciences (EXAS) PT Raised to $67.00 at Bank of AmericaEXACT Sciences (EXAS) PT Raised to $67.00 at Bank of America
www.americanbankingnews.com - November 29 at 11:34 AM
Where Exact Sciences Corporation (EXAS) Stands In Terms Of Earnings Growth Against Its IndustryWhere Exact Sciences Corporation (EXAS) Stands In Terms Of Earnings Growth Against Its Industry
finance.yahoo.com - November 28 at 8:58 AM
ETFs with exposure to EXACT Sciences Corp. : November 27, 2017ETFs with exposure to EXACT Sciences Corp. : November 27, 2017
finance.yahoo.com - November 27 at 5:51 PM
Leerink Swann Reaffirms Outperform Rating for EXACT Sciences Co. (EXAS)Leerink Swann Reaffirms Outperform Rating for EXACT Sciences Co. (EXAS)
www.americanbankingnews.com - November 27 at 12:34 AM
Exact Sciences Corporation (EXAS) Insider Kevin T. Conroy Sells 134,057 SharesExact Sciences Corporation (EXAS) Insider Kevin T. Conroy Sells 134,057 Shares
www.americanbankingnews.com - November 22 at 7:28 PM
Exact Sciences Corp (EXAS) President and CEO Kevin T Conroy Sold $8 million of SharesExact Sciences Corp (EXAS) President and CEO Kevin T Conroy Sold $8 million of Shares
finance.yahoo.com - November 22 at 7:12 PM
Exact Sciences, We Bid You FarewellExact Sciences, We Bid You Farewell
seekingalpha.com - November 21 at 6:41 PM
Exact Sciences Corporation (EXAS) Receives Average Recommendation of "Buy" from AnalystsExact Sciences Corporation (EXAS) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 20 at 3:48 PM
Roka Bioscience (ROKA) versus Exact Sciences Corporation (EXAS) Financial ContrastRoka Bioscience (ROKA) versus Exact Sciences Corporation (EXAS) Financial Contrast
www.americanbankingnews.com - November 19 at 3:28 PM
EXACT Sciences (EXAS) Presents At Jefferies 2017 London Healthcare Conference - SlideshowEXACT Sciences (EXAS) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
seekingalpha.com - November 17 at 5:18 PM
ETFs with exposure to EXACT Sciences Corp. : November 17, 2017ETFs with exposure to EXACT Sciences Corp. : November 17, 2017
finance.yahoo.com - November 17 at 12:14 PM
Exact Sciences breaks ground on lab, office expansions in MadisonExact Sciences breaks ground on lab, office expansions in Madison
finance.yahoo.com - November 16 at 2:07 PM
$76.55 Million in Sales Expected for Exact Sciences Corporation (EXAS) This Quarter$76.55 Million in Sales Expected for Exact Sciences Corporation (EXAS) This Quarter
www.americanbankingnews.com - November 16 at 11:02 AM
Even Exact Sciences Bulls Wonder If Expectations Are LoftyEven Exact Sciences Bulls Wonder If Expectations Are Lofty
finance.yahoo.com - November 13 at 7:00 PM
Exact Sciences Corporation (EXAS) CEO Sells $8,149,787.70 in StockExact Sciences Corporation (EXAS) CEO Sells $8,149,787.70 in Stock
www.americanbankingnews.com - November 13 at 4:20 PM
Is Exact Sciences Corporation Stock a Buy?Is Exact Sciences Corporation Stock a Buy?
www.fool.com - November 13 at 9:25 AM
Short Interest in Exact Sciences Corporation (EXAS) Declines By 17.9%Short Interest in Exact Sciences Corporation (EXAS) Declines By 17.9%
www.americanbankingnews.com - November 12 at 4:30 AM
Todays Research Reports on Trending Tickers: Exact Sciences and Gilead SciencesToday's Research Reports on Trending Tickers: Exact Sciences and Gilead Sciences
finance.yahoo.com - November 9 at 2:38 AM
Exact Sciences to Expand Laboratory and Corporate Facilities in MadisonExact Sciences to Expand Laboratory and Corporate Facilities in Madison
finance.yahoo.com - November 9 at 2:38 AM
Head to Head Review: Crispr Theraptc (CRSP) and Exact Sciences Corporation (EXAS)Head to Head Review: Crispr Theraptc (CRSP) and Exact Sciences Corporation (EXAS)
www.americanbankingnews.com - November 7 at 11:44 AM
ETFs with exposure to EXACT Sciences Corp. : November 6, 2017ETFs with exposure to EXACT Sciences Corp. : November 6, 2017
finance.yahoo.com - November 6 at 8:15 PM
Anatomy of Success: Exact Sciences Corp (EXAS)Anatomy of Success: Exact Sciences Corp (EXAS)
finance.yahoo.com - November 6 at 8:15 PM
Why Investors Are Paying a Premium for EXACT Sciences Corporation - Motley FoolWhy Investors Are Paying a Premium for EXACT Sciences Corporation - Motley Fool
www.fool.com - November 4 at 11:52 PM
Traders Purchase Large Volume of Put Options on Exact Sciences Corporation (EXAS)Traders Purchase Large Volume of Put Options on Exact Sciences Corporation (EXAS)
www.americanbankingnews.com - November 4 at 1:56 AM
Why Exact Sciences Shares Rallied 16.7% in OctoberWhy Exact Sciences Shares Rallied 16.7% in October
finance.yahoo.com - November 3 at 6:51 PM
Exact Sciences Corporation (EXAS) Insider Graham Peter Lidgard Sells 45,775 SharesExact Sciences Corporation (EXAS) Insider Graham Peter Lidgard Sells 45,775 Shares
www.americanbankingnews.com - November 3 at 5:24 PM
Daily Technical Summary Reports on Medical Research Stocks -- Exact Sciences, HTG Molecular Diagnostics, Roka Bioscience, and OpGenDaily Technical Summary Reports on Medical Research Stocks -- Exact Sciences, HTG Molecular Diagnostics, Roka Bioscience, and OpGen
www.bizjournals.com - November 3 at 12:34 PM
EXACT Sciences Corp. :EXAS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017EXACT Sciences Corp. :EXAS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 3 at 12:34 PM
Why Investors Are Paying a Premium for EXACT Sciences CorporationWhy Investors Are Paying a Premium for EXACT Sciences Corporation
finance.yahoo.com - November 3 at 12:34 PM
Exact Sciences to participate in two investor conferences during NovemberExact Sciences to participate in two investor conferences during November
finance.yahoo.com - November 2 at 7:47 PM
Exact Sciences Corporation (EXAS) & Its Rivals Financial ComparisonExact Sciences Corporation (EXAS) & Its Rivals Financial Comparison
www.americanbankingnews.com - November 2 at 7:22 PM
Exact Sciences Corporation (EXAS) Rating Lowered to Hold at Zacks Investment ResearchExact Sciences Corporation (EXAS) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - November 2 at 7:04 PM
FY2017 EPS Estimates for Exact Sciences Corporation Boosted by Analyst (EXAS)FY2017 EPS Estimates for Exact Sciences Corporation Boosted by Analyst (EXAS)
www.americanbankingnews.com - November 2 at 9:10 AM
Leerink Swann Research Analysts Lift Earnings Estimates for Exact Sciences Corporation (EXAS)Leerink Swann Research Analysts Lift Earnings Estimates for Exact Sciences Corporation (EXAS)
www.americanbankingnews.com - November 2 at 9:10 AM
FY2017 EPS Estimates for Exact Sciences Corporation Increased by Jefferies Group (EXAS)FY2017 EPS Estimates for Exact Sciences Corporation Increased by Jefferies Group (EXAS)
www.americanbankingnews.com - November 2 at 9:10 AM
Exact Sciences (EXAS) Looks Good: Stock Adds 9.8% in SessionExact Sciences (EXAS) Looks Good: Stock Adds 9.8% in Session
finance.yahoo.com - November 1 at 7:39 PM

SEC Filings

EXACT Sciences (NASDAQ:EXAS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

EXACT Sciences (NASDAQ:EXAS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

EXACT Sciences (NASDAQ EXAS) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.